Evidence map›Paper›PMID 26308966›Full record

Observational studyJAMA psychiatry2015

Early Cannabis Use, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence.

Leon French, Courtney Gray, Gabriel Leonard, Michel Perron, G Bruce Pike, Louis Richer, Jean R Séguin, Suzanne Veillette, C John Evans, Eric Artiges and 28 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in JAMA psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 7 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 7 syntheses or guidelines pooled it, 175 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Independent brain cortical signatures of risk for adolescent cannabis use and consequences of such use are moderated by sex.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Cannabis and Tobacco Co-Use Predicts Psychosis in Clinical High Risk Cohorts.medRxiv : the preprint server for health sciences · 2025
    Article
  15. Review
  16. Cells and Molecules Underpinning Cannabis-Related Variations in Cortical Thickness during Adolescence.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  17. Review
  18. The Role of Cannabis in the Development of Psychosis.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2024
    Review
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 20 institutions in 6 countries.

Leon FrenchRotman Research Institute, Baycrest, Toronto, Ontario, Canada.
Courtney GrayRotman Research Institute, Baycrest, Toronto, Ontario, Canada.
Gabriel LeonardMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Michel PerronGroupe d'Étude des Conditions de vie et des Besoins de la Population, Cégep de Jonquiere, Jonquiere, Saguenay, Quebec, Canada 4Department of Human Sciences, University of Quebec in Chicoutimi, Chicoutimi, Quebec, Canada.
G Bruce PikeDepartment of Radiology, University of Calgary, Calgary, Alberta, Canada6Department of Clinical Neuroscience, University of Calgary, Calgary, Alberta, Canada.
Louis RicherDepartment of Health Sciences, University of Quebec in Chicoutimi, Chicoutimi, Quebec, Canada.
Jean R SéguinDepartment of Psychiatry and Centre de Recherche du Centre Hospitalier Universitaire Ste-Justine, University de Montréal, Montreal, Quebec, Canada.
Suzanne VeilletteGroupe d'Étude des Conditions de vie et des Besoins de la Population, Cégep de Jonquiere, Jonquiere, Saguenay, Quebec, Canada 4Department of Human Sciences, University of Quebec in Chicoutimi, Chicoutimi, Quebec, Canada.
C John EvansSchool of Psychology, Cardiff University, Cardiff, Wales.
Eric ArtigesInstitut National de la Santé et de la Recherche Medicale (INSERM), Unité Mixte de Recherche (UMR) 1000, Research Unit Imaging and Psychiatry, Commissariat à l'Énergie Atomique (CEA), Direction des Sciences du Vivant, Institut d'Imagerie Biomédicale, Serv.
Tobias BanaschewskiDepartment of Child and Adolescent Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Arun W L BokdeDiscipline of Psychiatry, School of Medicine and Trinity College Institute of Neurosciences, Trinity College, Dublin, Ireland.
Uli BrombergInstitut für Systemische Neurowissenschaften, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Ruediger BruehlPhysikalisch-Technische Bundesanstalt, Berlin, Germany.
Christian BuchelInstitut für Systemische Neurowissenschaften, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Anna CattrellInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, England20Medical Research Council-Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London.
Patricia J ConrodDepartment of Psychiatry and Centre de Recherche du Centre Hospitalier Universitaire Ste-Justine, University de Montréal, Montreal, Quebec, Canada19Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.
Herta FlorDepartment of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Vincent FrouinNeurospin, CEA-Saclay Center, Paris, France.
Jurgen GallinatInstitut für Systemische Neurowissenschaften, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Hugh GaravanDepartment of Psychiatry, University of Vermont, Burlington24Department of Psychology, University of Vermont, Burlington.
Penny GowlandSchool of Physics and Astronomy, University of Nottingham, Nottingham, England.
Andreas HeinzDepartment of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité, Universitätsmedizin Berlin, Berlin, Germany.
Herve LemaitreInstitut National de la Santé et de la Recherche Medicale (INSERM), Unité Mixte de Recherche (UMR) 1000, Research Unit Imaging and Psychiatry, Commissariat à l'Énergie Atomique (CEA), Direction des Sciences du Vivant, Institut d'Imagerie Biomédicale, Serv.
Jean-Luc MartinotInstitut National de la Santé et de la Recherche Medicale (INSERM), Unité Mixte de Recherche (UMR) 1000, Research Unit Imaging and Psychiatry, Commissariat à l'Énergie Atomique (CEA), Direction des Sciences du Vivant, Institut d'Imagerie Biomédicale, Serv.
Frauke NeesDepartment of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Dimitri Papadopoulos OrfanosNeurospin, CEA-Saclay Center, Paris, France.
Melissa Marie PangelinanRotman Research Institute, Baycrest, Toronto, Ontario, Canada.
Luise PoustkaDepartment of Child and Adolescent Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Marcella RietschelDepartment of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Michael N SmolkaDepartment of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.
Henrik WalterDepartment of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité, Universitätsmedizin Berlin, Berlin, Germany.
Robert WhelanDepartment of Psychology, University College Dublin, Dublin, Ireland.
Nic J TimpsonMedical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.
Gunter SchumannInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, England20Medical Research Council-Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London.
George Davey SmithMedical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.
Zdenka PausovaDepartment of Physiology and Experimental Medicine, Hospital for Sick Children, University of Toronto, Ontario, Canada31Department of Physiology, University of Toronto, Ontario, Canada32Department of Nutritional Sciences, University of Toronto, Ontario, C.
Tomáš PausRotman Research Institute, Baycrest, Toronto, Ontario, Canada33Department of Psychology, University of Toronto, Ontario, Canada34Department of Psychiatry, University of Toronto, Ontario, Canada35Child Mind Institute, New York, New York.
Baycrest Hospital · CACentral Institute of Mental Health · DECentre Hospitalier Universitaire Sainte-Justine · CACharité - Universitätsmedizin Berlin · DECommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRHeidelberg University · DEInserm · FRKing's College London · GBUniversité du Québec à Chicoutimi · CAUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Toronto · CACardiff University · GBCégep de Jonquière · CAInstitut d'Imagerie Biomédicale · FRMedical Research Council · GBMontreal Neurological Institute and Hospital · CAPhysikalisch-Technische Bundesanstalt · DETechnische Universität Dresden · DETrinity College Dublin · IEUniversität Hamburg · DE

Funding

Axon, Testosterone and Mental Health during AdolescenceR01MH085772 · NIMH · BAYCREST CENTRE FOR GERIATRIC CARE · PI PAUS, TOMAS · 2010 to 2014
$1.5M
CIHRMedical Research Council 092731Medical Research Council 93558Medical Research Council G0901858Medical Research Council G9815508Medical Research Council MC_PC_15018Medical Research Council MC_UU_12013/1NIMH NIH HHS R01 MH085772NIMH NIH HHS R01 MH085772-01A1Wellcome Trust 102215
6 · The paper itself

Abstract

importanceCannabis use during adolescence is known to increase the risk for schizophrenia in men. Sex differences in the dynamics of brain maturation during adolescence may be of particular importance with regard to vulnerability of the male brain to cannabis exposure.

objectiveTo evaluate whether the association between cannabis use and cortical maturation in adolescents is moderated by a polygenic risk score for schizophrenia. DESIGN, SETTING, AND

participantsObservation of 3 population-based samples included initial analysis in 1024 adolescents of both sexes from the Canadian Saguenay Youth Study (SYS) and follow-up in 426 adolescents of both sexes from the IMAGEN Study from 8 European cities and 504 male youth from the Avon Longitudinal Study of Parents and Children (ALSPAC) based in England. A total of 1577 participants (aged 12-21 years; 899 [57.0%] male) had (1) information about cannabis use; (2) imaging studies of the brain; and (3) a polygenic risk score for schizophrenia across 108 genetic loci identified by the Psychiatric Genomics Consortium. Data analysis was performed from March 1 through December 31, 2014. MAIN OUTCOMES AND MEASURES: Cortical thickness derived from T1-weighted magnetic resonance images. Linear regression tests were used to assess the relationships between cannabis use, cortical thickness, and risk score.

resultsAcross the 3 samples of 1574 participants, a negative association was observed between cannabis use in early adolescence and cortical thickness in male participants with a high polygenic risk score. This observation was not the case for low-risk male participants or for the low- or high-risk female participants. Thus, in SYS male participants, cannabis use interacted with risk score vis-à-vis cortical thickness (P = .009); higher scores were associated with lower thickness only in males who used cannabis. Similarly, in the IMAGEN male participants, cannabis use interacted with increased risk score vis-à-vis a change in decreasing cortical thickness from 14.5 to 18.5 years of age (t137 = -2.36; P = .02). Finally, in the ALSPAC high-risk group of male participants, those who used cannabis most frequently (≥61 occasions) had lower cortical thickness than those who never used cannabis (difference in cortical thickness, 0.07 [95% CI, 0.01-0.12]; P = .02) and those with light use (<5 occasions) (difference in cortical thickness, 0.11 [95% CI, 0.03-0.18]; P = .004). CONCLUSIONS AND RELEVANCE: Cannabis use in early adolescence moderates the association between the genetic risk for schizophrenia and cortical maturation among male individuals. This finding implicates processes underlying cortical maturation in mediating the link between cannabis use and liability to schizophrenia.

Indexed as

Adolescent DevelopmentGene-Environment InteractionAdolescentAge of OnsetBrainCerebral CortexChildCohort StudiesFemaleGenetic Predisposition to DiseaseHumansLinear ModelsLongitudinal StudiesMagnetic Resonance ImagingMaleMarijuana Smoking

Identifiers

PMID26308966
PMCPMC5075969
OpenAlexW1894823067

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.